Navigation Links
Neurobiological Technologies Reports Third Quarter Financial Results
Date:5/12/2008

. (ET) on May 13, 2008 through midnight on May 17, 2008. Replay number: (888) 203-1112 (U.S. and Canada) / (719) 457-0820 (international). Replay access code: 3838724.

About Neurobiological Technologies, Inc.

Neurobiological Technologies is a biopharmaceutical company focused on developing novel, first-in-class agents for central nervous system conditions and other serious unmet medical needs. The Company's most advanced product candidate, Viprinex(TM) (ancrod), is in Phase 3 clinical testing as a novel investigational drug with multiple mechanisms of action that is specifically designed to double the time period that patients can be treated after the onset of a stroke. NTI also has the right to receive royalty payments from sales of Namenda(R) (memantine HCL), an approved drug marketed for Alzheimer's disease, and the right to receive payments from the development and marketing of XERECEPT(R) (corticorelin acetate injection), an investigational drug in Phase 3 clinical development for swelling associated with brain tumors. Additionally, NTI has rights to two compounds in early-stage development for Alzheimer's and Huntington's diseases.

Forward-Looking Statements

Except for the historical information contained herein, the matters discussed in this press release are forward-looking statements that involve risks and uncertainties, including uncertainties regarding the timing for completion of clinical trials, obtaining approval for Viprinex, our levels of future expenditures and capital resources and our need to raise additional capital to fund our operations, as well as other risks detailed from time to time in our Annual Report of Form 10-K, and updated periodically in our Quarterly Reports on Form 10-Q, and other filings with the Securities and Exchange Commission. Actual results may differ materially from those projected. These forward-looking statements represent our judgment as of the date of the release. We undertake no obligation t
'/>"/>

SOURCE Neurobiological Technologies, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Neurobiological Technologies Sets Date for Third Quarter Financial Results
2. Neurobiological Technologies Reports Receipt of $2.0 Million Royalty Payment for Quarterly Sales of Memantine
3. Neurobiological Technologies Appoints Matthew M. Loar as Chief Financial Officer
4. Neurobiological Technologies Announces Amendment of License and Cooperation Agreement with Merz Pharmaceuticals and Childrens Hospital
5. Neurobiological Technologies Reports $2.1 Million Quarterly Payment for Sales of Memantine
6. Neurobiological Technologies Sets Date for Research and Development Day
7. Neurobiological Technologies, Inc. (Nasdaq: NTII) Q2/08 Review Issued By Scimitar Equity Research, Inc.
8. Update: Neurobiological Technologies Sets Date for Second Quarter Financial Results and Conference Call
9. Neurobiological Technologies Sets Date for Second Quarter Financial Results
10. Neurobiological Technologies, Inc. Reports Retirement of Ronald E. Cape, Ph.D., from Board
11. Neurobiological Technologies, Inc. (Nasdaq: NTII) Q1/08 Review Issued By Scimitar Equity Research, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... -- Bio-Techne Corporation (NASDAQ: TECH ) announced ... to serve in a newly created position of Senior ... will be responsible for managing the operations of Bio-Techne,s ... acquired in July 2014 and the recently acquired CyVek ... -based ProteinSimple develops and commercializes proprietary systems and consumables ...
(Date:11/24/2014)... WASHINGTON , Nov. 24, 2014  Last ... G.K. Butterfield (D-NC) took a bold ... diseases by introducing the OPEN Act. Original co-sponsors ... Hastings (D-FL). The Act will incentivize drug makers ... life-threatening rare diseases and pediatric cancers, which opens ...
(Date:11/24/2014)... Continental Clinical Solutions, LLC (Continental) focuses ... at its mid-Atlantic late-phase research facility, located in ... the idea of closing patient disparities in mind. ... advances," said Continental's CEO, Saleh Stevens . ... cell line of Henrietta Lacks, dubious ethical practices ...
(Date:11/23/2014)... Apiscent Labs, a privately held ... ingredients to the global pharmaceutical and flavor & ... website, Apiscent.com. , The Apiscent.com homepage welcomes visitors ... easy navigation, rotating images and content focused on ... , The company’s work in Pharmaceutical ...
Breaking Biology Technology:Bio?Techne Announces Appointment Of Robert Gavin As Leader Of New Protein Platforms Division 2Bio?Techne Announces Appointment Of Robert Gavin As Leader Of New Protein Platforms Division 3OPEN Act Introduced to Repurpose Drugs for Rare Diseases 2At Continental Clinical Solutions, CEO Saleh Stevens Focuses on Diversity in Clinical Trial Recruitment at Maryland Site 2At Continental Clinical Solutions, CEO Saleh Stevens Focuses on Diversity in Clinical Trial Recruitment at Maryland Site 3
... QUEBEC CITY, QC, Oct. 2 /PRNewswire-FirstCall/ - AEterna ... company focused on,endocrine therapy and oncology, will announce ... live webcast presentation and conference call hosted by,President ... the outcome,of management,s review of the Company,s pipeline ...
... /PRNewswire-FirstCall/ - Nventa,Biopharmaceuticals Corporation (TSX:NVN) announced today that Gregory M.,McKee, the ... conferences: BioContact Quebec 2007 (Quebec, Canada): ... Mr. McKee is scheduled to present on Thursday, October 4th at ... Salle Laval Room at the Fairmont Le ...
... Pa., Oct. 2 Monitorforhire.com, the,fastest source ... its,service even faster. The company has added ... and respond immediately to work requests via,PDA ... Scott Freedman, president of monitorforhire.com says ...
Cached Biology Technology:AEterna Zentaris Announces Outcome of Management's Strategic Review 2AEterna Zentaris Announces Outcome of Management's Strategic Review 3AEterna Zentaris Announces Outcome of Management's Strategic Review 4Nventa's CEO to present at two upcoming investor conferences 2
(Date:11/4/2014)... University of Utah engineers developed the first room-temperature fuel ... electricity without needing to ignite the fuel. These new ... off-grid power and sensors. , A study of the ... Society journal ACS Catalysis . , Fuel cells ... a fuel and an oxygen-rich source such as air. ...
(Date:11/4/2014)... 2014   3D ... Fuel3D , a developer of 3D scanning ... totaling $6.4 million (£4 million). This funding builds on the ... year and paves the way for the commercial launch of ... funding round was led by Chimera Partners and will be ...
(Date:11/3/2014)... , Nov. 3, 2014  NeuroSigma ® ... -based life sciences company focused on commercialization of ... for the treatment of neurological and neuropsychiatric ... Industrial Property has issued a Notice of Allowance ... application is co-owned by NeuroSigma and the Regents ...
Breaking Biology News(10 mins):Jet-fueled electricity at room temperature 2Fuel3D Secures $6.4 Million in Expansion Funding 2Fuel3D Secures $6.4 Million in Expansion Funding 3NeuroSigma Receives Notice of Allowance from the Mexican Institute of Industrial Property Covering Subcutaneous Trigeminal Nerve Stimulation (sTNS) 2NeuroSigma Receives Notice of Allowance from the Mexican Institute of Industrial Property Covering Subcutaneous Trigeminal Nerve Stimulation (sTNS) 3
... Calif., May 11, 2010 -- Investigators from around the ... Friday, May 7, to share their knowledge of the ... nucleic acids turn off proteins and have been implicated ... other conditions. "The discovery that small RNAs ...
... University have developed a rapid, high-throughput screening method for ... by Munkongdee et al, "Rapid diagnosis of α-thalassemia by ... of The Journal of Molecular Diagnostics . ... defect in the production of a component of hemoglobin. ...
... the 40 th annual meeting of the Society ... research findings on the brain, nervous system, and related ... meeting is the world,s largest source of emerging news ... will discuss how science and society can work together ...
Cached Biology News:Researchers share insights into RNA 2Actress Glenn Close to address stigma of mental illness at world's largest brain science meeting 2Actress Glenn Close to address stigma of mental illness at world's largest brain science meeting 3
... Disruption of the mitochondrial transmembrane ... intracellular events that occur following induction ... Detection Kit utilizes a lipophilic cation, ... activity marker. MitoLight is a mitochondrial ...
... ProteinChip arrays have been developed for ... samples. A variety of ProteinChip chemical ... according to their unique biochemical properties. ... allowing side-by-side sample comparison, and the ...
... VersArray ChipWriter Pro systems are ... proteins, or other biological samples. VersArray ... for uniformity, spot density, and reproducibility ... a variety of substrates. Their modular ...
... Ciphergen's ProteinChip arrays have been developed ... biological samples. A variety of ProteinChip ... proteins according to their unique biochemical ... spots, allowing side-by-side sample comparison, and ...
Biology Products: